Preoperative characteristics
|
Male sex
|
1091 (58.2%)
|
3636 (59.5%)
|
0.315
|
Age, years
|
58.0 (15.7)
|
62.1 (15.6)
|
<0.001
|
Body mass index, kg m−2
|
23.5 (3.6)
|
23.6 (3.8)
|
0.240
|
Surgery time, min
|
268.8 (150.9)
|
220.1 (147.6)
|
<0.001
|
ASA class
| | |
<0.001
|
1
|
433 (23.1%)
|
975 (15.9%)
| |
2
|
892 (47.5%)
|
3191 (52.2%)
|
≥ 3
|
551 (29.4%)
|
1949 (31.9%)
|
Cancer
|
405 (21.6%)
|
1840 (30.1%)
|
<0.001
|
eGFR*a, mL·min− 1·1.73·m−2
| | |
0.313
|
≥ 90
|
841 (44.8%)
|
2596 (42.5%)
| |
60–89
|
528 (28.1%)
|
1825 (29.8%)
| |
30–60
|
310 (16.5%)
|
1029 (16.8%)
| |
< 30
|
197 (10.5%)
|
665 (10.9%)
| |
Intraoperative characteristics
|
Type of operation
| | |
<0.001
|
Non-cardiovascular surgery
|
1567 (83.5%)
|
4786 (78.3%)
| |
Cardiovascular surgery
|
309 (16.5%)
|
1329 (21.7%)
| |
Emergency surgery
|
329 (17.5%)
|
781 (12.8%)
|
<0.001
|
Intraoperative hypotensionb
|
455 (24.3%)
|
1659 (27.1%)
|
0.013
|
Type of anesthesia
| | |
<0.001
|
General anesthesia
|
1823 (97.5%)
|
5474 (89.9%)
| |
Regional anesthesia
|
23 (1.2%)
|
278 (4.6%)
| |
Monitored anesthesia care
|
24 (1.3%)
|
335 (5.5%)
| |
Patient management (PODs 0–3)
|
NaCl 0.9% infused, mL kg−1
|
12.3 (13.2)
|
8.4 (9.5)
|
<0.001
|
NaCl 0.45% infused, mL kg− 1
|
6.5 (20.3)
|
2.9 (12.9)
|
<0.001
|
Balanced electrolyte solution infused, mL kg−1
|
41.9 (37.1)
|
49.7 (40.7)
|
<0.001
|
Free water containing dextrose, mL kg−1
|
47.2 (62.5)
|
59.3 (56.9)
|
<0.001
|
Hydroxyethyl starch infused, mL kg−1
|
22.1 (21.5)
|
13.4 (16.5)
|
<0.001
|
Intraoperative fluid balance, %c
|
1.8 (3.6)
|
1.7 (2.8)
|
0.321
|
RRT (without RRT history)
|
51 (2.7%)
|
135 (2.2%)
|
0.199
|
Use of inotropes/vasopressorsd
|
1635 (87.2%)
|
4286 (70.1%)
|
<0.001
|
Use of diureticse
|
1300 (69.3%)
|
3423 (56.0%)
|
<0.001
|
Use of radiocontrast
|
991 (52.8%)
|
1738 (28.4%)
|
<0.001
|
Use of nephrotoxic antibioticsf
|
377 (20.1%)
|
1147 (18.8%)
|
0.197
|
Use of NSAIDs
|
754 (40.2%)
|
2194 (35.9%)
|
0.001
|
Postoperative laboratory (PODs 0–3) and clinical outcomes
|
Maximum Cl−, mmol/L*
|
112.3 (2.9)
|
104.8 (3.3)
|
<0.001
|
Increase in Cl−, mmol/L**
|
5.6 (4.4)
|
3.5 (3.2)
|
<0.001
|
Postoperative metabolic acidosis (PODs 0–3)
|
262 (14.0%)
|
615 (10.1%)
|
<0.001
|
AKI occurrence
|
289 (15.4%)
|
898 (14.7%)
|
0.443
|
AKI stage ≥ 2 occurrence
|
51 (2.7%)
|
135 (2.2%)
|
0.199
|